tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Takeda’s Oveporexton Shows Promise in Phase 3 Narcolepsy Trials

Story Highlights
Takeda’s Oveporexton Shows Promise in Phase 3 Narcolepsy Trials

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from Takeda Pharmaceutical Co ( (JP:4502) ) is now available.

Takeda Pharmaceutical Co has presented promising data from its Phase 3 clinical trials of oveporexton (TAK-861), an investigational oral orexin receptor 2 agonist, at the World Sleep 2025 Congress. The studies demonstrated statistically significant improvements in narcolepsy type 1 symptoms, with no serious treatment-related adverse events reported, marking a potential breakthrough in addressing the underlying cause of this chronic neurological disease.

The most recent analyst rating on (JP:4502) stock is a Hold with a Yen4693.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.

More about Takeda Pharmaceutical Co

Takeda Pharmaceutical Co is a leading global biopharmaceutical company based in Japan, focusing on innovative medicines in areas such as oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. The company is recognized for its leadership in orexin science, particularly in developing treatments for narcolepsy type 1.

YTD Price Performance: 11.80%

Average Trading Volume: 4,216,741

Technical Sentiment Signal: Buy

Current Market Cap: Yen7249.6B

For detailed information about 4502 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1